Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
Toronto, Ontario--(Newsfile Corp. - March 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that recent in vitro data demonstrates an enhanced bladder cancer cell kill, when light-activated Ruvidar®
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-03-02 7:00 AM EST | Theralase Technologies Inc.
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March 2026. These high-profile meetings will provide Defence with multiple opportunities to advance strategic p
Biotechnology, Pharmaceuticals, Health
2026-03-02 3:15 AM EST | Defence Therapeutics Inc.
Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to
2026-02-27 5:21 PM EST | Sharp Therapeutics Corp.
Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million
Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the launch of a private placement (the "Private Placement") of up to 20,000,000 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of up to $11,000,000. Each Unit will be compris
Biotechnology, Pharmaceuticals, Health
2026-02-27 5:00 PM EST | Defence Therapeutics Inc.
Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has increased the size of its previously announced non-brokered private placement of non-transferable secured convertible debentures (the "Debentures") from u
2026-02-27 3:32 PM EST | Telo Genomics Corp.
Restart Life Sciences Closes Acquisition of Holy Crap Foods
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that it has successfully closed the previously announced acquisition of 100% of the issued and outstanding shares of Holy Crap Foods Inc. ("Holy Crap") pursuant to the definitive agreement dated February 12, 2026, among the Company, Happy Belly Coffee Inc., a subsidiary of Happy Belly Food Group
Technology, Biotechnology, Health
2026-02-27 8:00 AM EST | Restart Life Sciences Corp.
TempraMed Reports over 275 Clinicians Recommending VIVI Cap to Patients on Leading FrontrowMD Platform Across the United States
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that more than 275 physicians across the United States have recommended and included VIVI Cap in the offers available to their patients across FrontrowMD, a leading physician engagement and education platform.
Technology, Biotechnology, Pharmaceuticals, Health
2026-02-26 7:00 AM EST | TempraMed Technologies Ltd.
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally derived 5 mg psilocybin capsules under the Authorised Prescriber Scheme. The clinical a
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-26 7:00 AM EST | Optimi Health Corp.
Optimi Health berichtet über den frühen klinischen Einsatz natürlicher Psilocybin-Kapseln zur Behandlung therapieresistenter Depressionen in Australien
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 26. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller pharmazeutischer Psychedelika-Produkte in pharmazeutischer Qualität, gab heute bekannt, dass in Australien nun Patienten mit therapieresistenter Depression (TRD) unter dem Authorised Prescriber Scheme mit den natürlich gewonnenen 5-mg-Psilocybin-Kapseln d
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-26 7:00 AM EST | Optimi Health Corp.
Izotropic's "Izotropic Africa" Enters Partnership Discussions with the Mohammed VI Foundation for Science & Health
Sacramento, California--(Newsfile Corp. - February 25, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that, further to its February 18t
2026-02-25 8:00 AM EST | Izotropic Corporation
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-02-25 7:27 AM EST | Cardiol Therapeutics Inc.
Scryb Reports Positive Q1 2026: Cash Increased 50%, Liabilities Down 27%, Remains Largest Shareholder of Cybeats
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company") announces that it has filed its audited consolidated financial statements and Management's Discussion and Analysis for the fiscal quarter ended December 31, 2025 ("Q1 2026"). The filings are available on SEDAR+. Q1 2026 Highlights Cash position improved by 50% to $1.2 million (from $0.8 million at September 30, 2025), with working capital rising 6
Biotechnology, Healthcare and Hospitals, Health
2026-02-25 7:01 AM EST | Scryb Inc.
PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Canadian Patent Office has allowed Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This allowance represents a significant milestone in the protection of PreveCeutical's proprietary technologies aime
Biotechnology, Pharmaceuticals, Health
2026-02-25 3:00 AM EST | PreveCeutical Medical Inc.
Envoy Medical Regains Compliance with Nasdaq Listing Requirement
White Bear Lake, Minnesota--(Newsfile Corp. - February 24, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) through the alternatives permitted under Listing Rule 5550(b). As previously disclosed
Biotechnology, Healthcare and Hospitals
2026-02-24 8:00 AM EST | Envoy Medical, Inc.
Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space
White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of three new patents with one in the United States and two in Hong Kong, further expanding its intellectual property and reinforcing its competitive position in the cochlear implant industry. "We believe the future of the cochlear implant industry
Biotechnology, Healthcare and Hospitals
2026-02-23 8:00 AM EST | Envoy Medical, Inc.
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of canc
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-20 7:00 AM EST | Theralase Technologies Inc.
Sernova Biotherapeutics Announces Warrant Amendments
Ontario and Boston, Massachusetts--(Newsfile Corp. - February 20, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("the Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced that, subject to approval from the TSX, the Company intends to amend some of its outstanding warrants. The Company issued 20,852,100 warrants pursuant to a private
2026-02-20 7:00 AM EST | Sernova Biotherapeutics
Nextleaf Solutions Scales up CPG Brand Growth with an Enhanced National Commercial Platform
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor announced strategic enhancements to its commercial infrastructure, including appointment of Kindred Canada as its national sales agency partner, and the addition of enhanced distribution partners serving Manitoba and Saskatchewan. These initiatives
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-02-19 9:00 AM EST | Nextleaf Solutions Ltd.
Neural Therapeutics Announces CSE Application to Acquire Full Ownership of Hanf.com, Shareholder Meeting, SIO Agreement Amendment and Concurrent Financing
Toronto, Ontario--(Newsfile Corp. - February 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has formally applied to the Canadian Securities Exchange (the "CSE") for approval to acquire the remaining 69.25% interest in CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers. Ronnie Jaegermann, Chief Executive Officer of CWE, stated: "Hanf.com h
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 8:53 AM EST | Neural Therapeutics Inc.
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET. A live webcast will be available on Kiora's investor relations website, ir.kiorapharma.com, on the
Biotechnology, Pharmaceuticals
2026-02-19 8:30 AM EST | Kiora Pharmaceuticals, Inc.